Controlling Inflammation Improves Aging Skeletal Muscle Health.
Journal
Exercise and sport sciences reviews
ISSN: 1538-3008
Titre abrégé: Exerc Sport Sci Rev
Pays: United States
ID NLM: 0375434
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
pmc-release:
01
04
2024
pubmed:
2
2
2023
medline:
23
3
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Chronic inflammation is associated with a decline in aging skeletal muscle health. Inflammation also seems to interfere with the beneficial skeletal muscle adaptations conferred by exercise training in older individuals. We hypothesize that the cyclooxygenase pathway is partially responsible for this negative inflammatory influence on aging skeletal muscle health and plasticity.
Identifiants
pubmed: 36722844
doi: 10.1249/JES.0000000000000313
pii: 00003677-202304000-00001
pmc: PMC10033374
mid: NIHMS1868761
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-56Subventions
Organisme : NIA NIH HHS
ID : R01 AG020532
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038576
Pays : United States
Informations de copyright
Copyright © 2023 by the American College of Sports Medicine.
Références
Scott A, Khan KM, Cook JL, Duronio V. What is “inflammation”? Are we ready to move beyond Celsus? Br. J. Sports Med . 2004; 38:248–9.
Wallach D, Kang T-B, Kovalenko A. Concepts of tissue injury and cell death in inflammation: a historical perspective. Nat. Rev. Immunol . 2014; 14:51–9.
Elisia I, Lam V, Hofs E, et al. Effect of age on chronic inflammation and responsiveness to bacterial and viral challenges. PLoS One . 2017; 12:e0188881.
Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med . 2019; 25:1822–32.
Germolec D, Shipowski K, Frawley R, Evans E. Markers of inflammation. In: DeWitt JC, Rockwell CE, Bowman CC, editors. Immunotoxicity Testing Methods in Molecular Biology . New York, NY: Humana Press; 2018. p. 57–79.
Walker KA, Walston J, Gottesman RF, Kucharska-Newton A, Palta P, Windham BG. Midlife systemic inflammation is associated with frailty in later life: the ARIC Study. J. Gerontol . 2018; 74:343–9.
Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med . 1993; 119:771–8.
Lavillegrand JR, Garnier M, Spaeth A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann. Intensive Care . 2021; 11:1–10.
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol . 2017; 39:517–28.
Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med . 2020; 26:1636–43.
Alvarez-Rodriguez L, Lopez-Hoyos M, Munoz-Cacho P, Martinez-Taboada VM. Aging is associated with circulating cytokine dysregulation. Cell. Immunol . 2012; 273:124–32.
Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood . 2005; 105:2294–9.
Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci . 2000; 908:244–54.
Minciullo PL, Catalano A, Mandraffino G, et al. Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch. Immunol. Ther. Exp . 2016; 64:111–26.
Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med . 2006; 119:526.e529–17.
Nathan C. Points of control in inflammation. Nature . 2002; 420:846–52.
Nathan C, Ding A. Nonresolving inflammation. Cell . 2010; 140:871–82.
Feehan K, Gilroy DW. Is resolution the end of inflammation? Trends Mol. Med . 2019; 25:198–214.
Korotkova M, Lundberg IE. The skeletal muscle arachidonic acid cascade in health and inflammatory disease. Nat. Rev. Rheumatol . 2014; 10:295–303.
Merritt E, Stec M, Thalacker-Mercer A, et al. Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans. J. Appl. Physiol . 2013; 115:937–48.
Peake J, Della Gatta P, Cameron-Smith D. Aging and its effects on inflammation in skeletal muscle at rest and following exercise-induced muscle injury. Am. J. Physiol. Regul. Integr. Comp. Physiol . 2010; 298:R1485–95.
Lavin KM, Perkins RK, Jemiolo B, Raue U, Trappe SW, Trappe TA. Effects of aging and lifelong aerobic exercise on basal and exercise-induced inflammation. J. Appl. Physiol . 2020; 128:87–99.
Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev . 2004; 56:387–437.
Korotkova M, Jakobsson P-J. Persisting eicosanoid pathways in rheumatic diseases. Nat. Rev. Rheumatol . 2014; 10:229–41.
Trappe TA, Liu SZ. Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise. J. Appl. Physiol . 2013; 115:909–19.
Lone AM, Giansanti P, Jørgensen MJ, et al. Systems approach reveals distinct and shared signaling networks of the four PGE 2 receptors in T cells. Sci. Signal . 2021; 14:eabc8579.
Wang D, DuBois RN. Role of prostanoids in gastrointestinal cancer. J. Clin. Invest . 2018; 128:2732–42.
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res . 2009; 50:S423–8.
Norel X, Sugimoto Y, Ozen G, et al. International Union of Basic and Clinical Pharmacology. CIX. Differences and similarities between human and rodent prostaglandin E2 receptors (EP1-4) and prostacyclin receptor (IP): specific roles in pathophysiologic conditions. Pharmacol. Rev . 2020; 72:910–68.
Cohen H, Pieper C, Harris T, Rao K, Currie M. The association of plasma IL-6 levels with functional disability in community dwelling elderly. J. Gerontol . 1997; 52A:M201–8.
Ferrucci L, Harris T, Guralnik J, et al. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc . 1999; 47:639–46.
Ferrucci L, Penninx BW, Volpato S, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J. Am. Geriatr. Soc . 2002; 50:1947–54.
Visser M, Pahor M, Taaffe D, et al. Relationship of Interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J. Gerontol . 2002; 57:M326–32.
Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J. Gerontol . 2009; 64:1183–9.
Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI Study. J. Gerontol . 2004; 59:242–8.
Mikkelsen UR, Couppé C, Karlsen A, et al. Life-long endurance exercise in humans: circulating levels of inflammatory markers and leg muscle size. Mech. Ageing Dev . 2013; 134:531–40.
Norheim KL, Cullum CK, Andersen JL, Kjaer M, Karlsen A. Inflammation relates to resistance training-induced hypertrophy in elderly patients. Med. Sci. Sports Exerc . 2017; 49:1079–85.
Grosicki GJ, Barrett BB, Englund DA, et al. Circulating interleukin-6 is associated with skeletal muscle strength, quality, and functional adaptation with exercise training in mobility-limited older adults. J. Frailty Aging . 2020; 9:57–63.
Marriott K, Chopp-Hurley J, Loukov D, et al. Muscle strength gains after strengthening exercise explained by reductions in serum inflammation in women with knee osteoarthritis. Clin. Biochem . 2021; 86:105381.
Hangelbroek RWJ, Knuiman P, Tieland M, de Groot LCPGM. Attenuated strength gains during prolonged resistance exercise training in older adults with high inflammatory status. Exp. Gerontol . 2018; 106:154–8.
Smith WL, Urade Y, Jakobsson P-J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev . 2011; 111:5821–65.
Standley RA, Liu SZ, Jemiolo B, Trappe SW, Trappe TA. Prostaglandin E 2 induces transcription of skeletal muscle mass regulators interleukin-6 and muscle RING finger-1 in humans. Prostaglandins Leukot. Essent. Fatty Acids . 2013; 88:361–4.
Wang P, Zhu F, Konstantopoulos K. Interleukin-6 synthesis in human chondrocytes is regulated via the antagonistic actions of prostaglandin (PG)E2 and 15-deoxy-Δ(12,14)-PGJ2. PLoS One . 2011; 6:e27630.
Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation. Am. J. Physiol. Cell Physiol . 2010; 298:C1445–56.
Fiebich B, Schleicher S, Spleiss O, Czygan M, Hüll M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem . 2001; 79:950–8.
St-Jacques B, Ma W. Role of prostaglandin E2 in the synthesis of the pro-inflammatory cytokine interleukin-6 in primary sensory neurons: an in vivo and in vitro study. J. Neurochem . 2011; 118:841–54.
van Hall G, Steensberg A, Fischer C, et al. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J. Clin. Endocrinol. Metab . 2008; 93:2851–8.
Toth MJ, Matthews DE, Tracy RP, Previs MJ. Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. Am. J. Physiol. Endocrinol. Metab . 2005; 288:E883–91.
Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. (1985) . 2005; 98:911–7.
Bodell PW, Kodesh E, Haddad F, Zaldivar FP, Cooper DM, Adams GR. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J. Appl. Physiol. (1985) . 2009; 106:443–53.
Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science . 2001; 294:1704–8.
Sandri M. Signaling in muscle atrophy and hypertrophy. Phys. Ther . 2008; 23:160–70.
Landi F, Marzetti E, Liperoti R, et al. Nonsteroidal anti-inflammatory drug (NSAID) use and sarcopenia in older people: results from the ilSIRENTE study. J. Am. Med. Dir. Assoc . 2013; 14:626.e629–13.
Trappe TA, Carroll CC, Dickinson JM, et al. Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am. J. Physiol. Regul. Integr. Comp. Physiol . 2011; 300:R655–62.
Trappe TA, Standley RA, Jemiolo B, Carroll CC, Trappe SW. Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults. Am. J. Physiol. Regul. Integr. Comp. Physiol . 2013; 304:R198–205.
Trappe TA, Ratchford SM, Brower BE, et al. COX inhibitor influence on skeletal muscle fiber size and metabolic adaptations to resistance exercise in older adults. J. Gerontol . 2016; 71:1289–94.
Liu SZ, Jemiolo B, Lavin KM, Lester BE, Trappe SW, Trappe TA. Prostaglandin E 2 /cyclooxygenase pathway in human skeletal muscle: influence of muscle fiber type and age. J. Appl. Physiol . 2016; 120:546–51.
Trappe TA, Fluckey JD, White F, Lambert CP, Evans WJ. Skeletal muscle PGF(2)(alpha) and PGE(2) in response to eccentric resistance exercise: influence of ibuprofen acetaminophen. J. Clin. Endocrinol. Metab . 2001; 86:5067–70.
Rieu I, Magne H, Savary-Auzeloux I, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J. Physiol . 2009; 587:5483–92.
Trappe TA, White F, Lambert CP, Cesar D, Hellerstein M, Evans WJ. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am. J. Physiol. Endocrinol. Metab . 2002; 282:E551–6.
Mikkelsen UR, Langberg H, Helmark IC, et al. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise. J. Appl. Physiol . 2009; 107:1600–11.
Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J. Appl. Physiol . 2007; 103:425–31.
Markworth JF, Vella L, Lingard BS, et al. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol . 2013; 305:R1281–96.
Markworth JF, Vella LD, Figueiredo VC, Cameron-Smith D. Ibuprofen treatment blunts early translational signaling responses in human skeletal muscle following resistance exercise. J. Appl. Physiol . 2014; 117:20–8.
Lilja M, Mandić M, Apro W, et al. High doses of anti-inflammatory drugs compromise muscle strength and hypertrophic adaptations to resistance training in young adults. Acta Physiol (Oxf.) . 2018; 222:e12948.
Vella L, Markworth JF, Peake JM, Snow RJ, Cameron-Smith D, Russell AP. Ibuprofen supplementation and its effects on NF-κB activation in skeletal muscle following resistance exercise. Physiol. Rep . 2014; 2:e12172.
Vella L, Markworth JF, Paulsen G, et al. Ibuprofen ingestion does not affect markers of post-exercise muscle inflammation. Front. Physiol . 2016; 7:86.
Krentz JR, Quest B, Farthing JP, Quest DW, Chilibeck PD. The effects of ibuprofen on muscle hypertrophy, strength, and soreness during resistance training. Appl. Physiol. Nutr. Metab . 2008; 33:470–5.
Cardinale DA, Lilja M, Mandić M, Gustafsson T, Larsen FJ, Lundberg TR. Resistance training with co-ingestion of anti-inflammatory drugs attenuates mitochondrial function. Front. Physiol . 2017; 8:1074.
Dideriksen K, Boesen A, Kristiansen J, et al. Skeletal muscle adaptation to immobilization and subsequent retraining in elderly men: no effect of anti-inflammatory medication. Exp. Gerontol . 2016; 82:8–18.
Dideriksen K, Reitelseder S, Malmgaard-Clausen NM, et al. No effect of anti-inflammatory medication on postprandial and postexercise muscle protein synthesis in elderly men with slightly elevated systemic inflammation. Exp. Gerontol . 2016; 83:120–9.
Petersen SG, Miller BF, Hansen M, Kjaer M, Holm L. Exercise and NSAIDs: effect on muscle protein synthesis in patients with knee osteoarthritis. Med. Sci. Sports Exerc . 2011; 43:425–31.
Petersen SG, Beyer N, Hansen M, et al. Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients. Arch. Phys. Med. Rehabil . 2011; 92:1185–93.
Jankowski CM, Gozansky WS, MacLean PS, et al. N-acetyl-4-aminophenol and musculoskeletal adaptations to resistance exercise training. Eur. J. Appl. Physiol . 2013; 113:1127–36.
Jankowski C, Shea K, Barry D, et al. Timing of ibuprofen use and musculoskeletal adaptations to exercise training in older adults. Bone Reports . 2015; 1:1–8.
Candow DG, Chilibeck PD, Weisgarber K, Vogt E, Baxter-Jones AD. Ingestion of low-dose ibuprofen following resistance exercise in postmenopausal women. J. Cachexia. Sarcopenia Muscle . 2013; 4:41–6.
Duff WR, Chilibeck PD, Candow DG, et al. Effects of ibuprofen and resistance training on bone and muscle: a randomized controlled trial in older women. Med. Sci. Sports Exerc . 2017; 49:633–40.
Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res . 2003; 18:1795–802.
Fountain WA, Naruse M, Claiborne A, et al. Low-dose aspirin and COX inhibition in human skeletal muscle. J. Appl. Physiol . 2020; 129:1477–82.
Naruse M, Fountain WA, Claiborne A, et al. Influence of low-dose aspirin, resistance exercise, and sex on human skeletal muscle PGE2 /COX pathway activity. Physiol. Rep . 2021; 9:e14790.
Ratchford SM, Lavin KM, Perkins RK, Jemiolo B, Trappe SW, Trappe TA. Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle. J. Appl. Physiol . 2017; 123:1610–6.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet . 2011; 377:31–41.
Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet . 2012; 379:1602–12.
Kern S, Skoog I, Östling S, Kern J, Börjesson-Hanson A. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open . 2012; 2:e001288.